Boston Pharmaceuticals
Boston - Model BOS-421 - Brain Penetrant Inhibitor
BOS-421 is a highly selective, brain penetrant RIPK1 inhibitor.
Most popular related searches
pro-inflammatory cytokine
immune inflammatory
inflammation inducing
induced inflammation
inflammatory cytokine
cytokine
apoptosis
cytokine receptor
inflammatory immunity
inflammatory immune
- RIPK1 is a member of the receptor-interacting Serine/Threonine kinase family containing an amino-terminal kinase domain, an intermediate domain and a carboxy-terminal death domain. RIPK1 is a key signalling node in regulating inflammation and cell death in response to signals including TNF family of cytokines, TLR3/TLR4 receptor activation, sensors of viral infection, and interferons.
- BOS-421 may have activity in the treatment of neurodegenerative conditions through multiple mechanisms, including inhibition of inflammation-induced cell death (necroptosis and apoptosis) and inhibition of the production of certain pro-inflammatory cytokines.